Organon-run study finds positive top-line Phase III results in dysmenorrhea

Organon KK, a Japan subsidiary of Organon & Co (NYSE: OGN), announced that the primary endpoint was achieved in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A, which is being developed as a treatment for dysmenorrhea.

Based on the results obtained from the trial, Organon KK will prepare an application for marketing approval and launch in Japan.

OG-8276A is a combination of desogestrel and ethinylestradiol. It has been marketed under the brand name Mercilon as an oral contraceptive and is currently sold by Organon in 51 countries worldwide, excluding Japan. Organon initiated development of the drug in Japan to address the unmet needs of Japanese patients with dysmenorrhea. Further analysis of the trial details will be conducted, and the findings may be published later.